These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 16107719)

  • 21. Active and inactive conformations of the epidermal growth factor receptor.
    Ferguson KM
    Biochem Soc Trans; 2004 Nov; 32(Pt 5):742-5. PubMed ID: 15494003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor (EGFR) signaling in cancer.
    Normanno N; De Luca A; Bianco C; Strizzi L; Mancino M; Maiello MR; Carotenuto A; De Feo G; Caponigro F; Salomon DS
    Gene; 2006 Jan; 366(1):2-16. PubMed ID: 16377102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bivalence of EGF-like ligands drives the ErbB signaling network.
    Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
    EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A model for the activation of the epidermal growth factor receptor kinase involvement of an asymmetric dimer?
    Groenen LC; Walker F; Burgess AW; Treutlein HR
    Biochemistry; 1997 Apr; 36(13):3826-36. PubMed ID: 9092812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation.
    Yang N; Wang X; Jiang J; Frank SJ
    Mol Endocrinol; 2007 Jul; 21(7):1642-55. PubMed ID: 17456794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for extended YFP-EGFR dimers in the absence of ligand on the surface of living cells.
    Kozer N; Henderson C; Jackson JT; Nice EC; Burgess AW; Clayton AH
    Phys Biol; 2011 Dec; 8(6):066002. PubMed ID: 21946082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling the epidermal growth factor -- epidermal growth factor receptor l2 domain interaction: implications for the ligand binding process.
    Jorissen RN; Treutlein HR; Epa VC; Burgess AW
    J Biomol Struct Dyn; 2002 Jun; 19(6):961-72. PubMed ID: 12023799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dimer interface of transmembrane domains for neu/erbB-2 receptor dimerization and transforming activation: a model revealed by molecular dynamics simulations.
    Sajot N; Genest M
    J Biomol Struct Dyn; 2001 Aug; 19(1):15-31. PubMed ID: 11565846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dimerization drives PDGF receptor endocytosis through a C-terminal hydrophobic motif shared by EGF receptor.
    Pahara J; Shi H; Chen X; Wang Z
    Exp Cell Res; 2010 Aug; 316(14):2237-50. PubMed ID: 20580638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization.
    Shan Y; Eastwood MP; Zhang X; Kim ET; Arkhipov A; Dror RO; Jumper J; Kuriyan J; Shaw DE
    Cell; 2012 May; 149(4):860-70. PubMed ID: 22579287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R
    Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A structure-based model for ligand binding and dimerization of EGF receptors.
    Klein P; Mattoon D; Lemmon MA; Schlessinger J
    Proc Natl Acad Sci U S A; 2004 Jan; 101(4):929-34. PubMed ID: 14732694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural insight into the specific interaction between murine SHPS-1/SIRP alpha and its ligand CD47.
    Nakaishi A; Hirose M; Yoshimura M; Oneyama C; Saito K; Kuki N; Matsuda M; Honma N; Ohnishi H; Matozaki T; Okada M; Nakagawa A
    J Mol Biol; 2008 Jan; 375(3):650-60. PubMed ID: 18045614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced ability of transforming growth factor-alpha to induce EGF receptor heterodimerization and downregulation suggests a mechanism of oncogenic synergy with ErbB2.
    Gulliford TJ; Huang GC; Ouyang X; Epstein RJ
    Oncogene; 1997 Oct; 15(18):2219-23. PubMed ID: 9393980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGF receptor activation: push comes to shove.
    Hubbard SR
    Cell; 2006 Jun; 125(6):1029-31. PubMed ID: 16777592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of the dimerization of proteins from the epidermal growth factor receptor family by single wavelength fluorescence cross-correlation spectroscopy.
    Liu P; Sudhaharan T; Koh RM; Hwang LC; Ahmed S; Maruyama IN; Wohland T
    Biophys J; 2007 Jul; 93(2):684-98. PubMed ID: 17468161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha.
    Garrett TP; McKern NM; Lou M; Elleman TC; Adams TE; Lovrecz GO; Zhu HJ; Walker F; Frenkel MJ; Hoyne PA; Jorissen RN; Nice EC; Burgess AW; Ward CW
    Cell; 2002 Sep; 110(6):763-73. PubMed ID: 12297049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The EGFR family: not so prototypical receptor tyrosine kinases.
    Lemmon MA; Schlessinger J; Ferguson KM
    Cold Spring Harb Perspect Biol; 2014 Apr; 6(4):a020768. PubMed ID: 24691965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model".
    Purba ER; Saita EI; Maruyama IN
    Cells; 2017 Jun; 6(2):. PubMed ID: 28574446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor.
    Lu C; Mi LZ; Grey MJ; Zhu J; Graef E; Yokoyama S; Springer TA
    Mol Cell Biol; 2010 Nov; 30(22):5432-43. PubMed ID: 20837704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.